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SUMMARY
Platelet aggregation was examined in a group of 35 non-smokers and 15
smokers who were receiving the contraceptive pill (30pg ethinyloestradiol and
norgestrel or norethisterone). Platelet aggregation induced by ATP was greater
after 4-6 months on the contraceptive pill in both smokers and non-smokers,
and there was no difference between the two groups. The increased risk of
thromboembolic disease in smokers on the contraceptive pill would appear to be
unrelated to effects on the platelet.
INTRODUCTION
Oral contraceptives have been available for over 20 years and, despite several
highly publicised articles on their adverse effects, they have remained one of the
most popular methods of contraception throughout the world. A variety of
epidemiological studies have linked their use with an increased incidence of
venous and arterial thromboembolism, and cigarette smoking has been strongly
associated with this increased risk, at least with regard to arterial thrombosis.I
Recent interest has focused on the effects of oral contraceptives on blood
coagulation factors and platelet function.2 Previous studies have shown an
increase in platelet aggregation in women receiving the contraceptive pill.3'4
Cigarette smoking is also a major factor for the development of cardiovascular
disease. It has been suggested that both endothelial and platelet factors are
involved in the effect of smoking. Although an effect on endothelial damage has
largely been confirmed,5' 6 data dealing with platelet function are conflicting.7' 8
Since epidemiological studies show an increased risk for women who are
smokers and are receiving the contraceptive pill,9 this study was carried out to
see if this increased risk could be related to effects on the platelet.
METHODS
Women who were intending to start the contraceptive pill were recruited from a
local family planning clinic. Informed consent was obtained from all subjects.
Ethical approval had been obtained from the Research Ethical Committee of the
Department of Therapeutics and Pharmacology, The Queen's University and Belfast City Hospital,
Belfast BT9 7BL.
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Queen's University of Belfast. Ofthe 80 subjects recruited for the study, only 50
completed the protocol. Their ages ranged from 17 to 31 years (mean 22 years).
Thirty-five were non-smokers and 15 were smokers (mean consumption 15
cigarettes per day). Patients who were on any other regular medication, had any
abnormality of their haematological indices or serum lipids, or who had received
an oral contraceptive within the previous six months, were excluded from the
study. Blood samples were taken for estimation of platelet aggregation before
starting the contraceptive pill and four to six months after treatment. All subjects
received a combination of 30pg of ethinyloestradiol in combination with
150-250pg of levonorgestrel or 1-5mg norethisterone.
For measurement of platelet aggregation, 20ml venous blood was obtained and
immediately anticoagulated with 3-8% sodium citrate using nine parts blood and
one part citrate by volume. After inversion and gentle mixing this was centrifuged
at 200g for 10 minutes. The platelet-rich plasma was removed with a plastic
pipette and diluted with saline to give a platelet concentration of4 x 108 cells/ml.
One ml aliquots of this were pipetted into siliconized cuvettes and placed in
the heated block of an aggregometer. When the sample stablilized at 37°C a
magnetic stir-bar and the impedence electrode were inserted into the cuvette.
The aggregometer and recorder werethen brought to zero atthe pre-set baseline
and calibrated using the integral 5 ohm resistance. The recorder was started
immediately after the addition of 10pi of aggregation agent. After four minutes
for ADP or seven minutes for adrenaline, the recorder was stopped,
the pen deflection measured and the impedence of ohms calculated. These
agents were used because they have been the two most commonly employed in
similar studies examining platelet aggregation with the contraceptive pill. The
aggregating reagents used were supplied by the Sigma Chemical Company and
were designed to produce a final concentration of 2 mmol/l in the prepared
sample. Comparisons between baseline and 4 -6 months of therapy and
between smokers and non-smokers were made using a paired t test. Values are
expressed as the mean ± standard deviation of the mean.
RESULTS
Adrenaline failed to induce platelet aggregation in several patients. We therefore
excluded those patients who had a response oflessthan 3 ohms (sensitivity ofthe
method) from further analysis. On this basis we were able to analyse data in 22
non-smokers and seven smokers. By contrast, platelet aggregation induced by
ADP occurred with all samples.
No change in adrenaline -induced platelet aggregation was observed, either
between baseline and the effects at 4-6 months or between smokers and non -
smokers. There was a significant increase in ADP induced platelet aggregation
in the 35 non-smokers and 15 smokers (p < 0 05). There was no significant
difference observed between the two groups (Fig).
DISCUSSION
Two different approaches have been used to study the effects of oral contra -
ceptives on blood clotting. One technique is to perform large-scale prospective
and retrospective studiesofwomen receivingthecontraceptive pill and determine
the incidence of thromboembolic complications as compared with a control
group. The other method is to study the effects of oral contraceptives on blood
coagulation and platelet function in smaller groups of women. The techniques
© The Ulster Medical Society, 1988.
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FIGURE
Measurement ofelectrical impedance (ohms) due to platelet aggregation induced
by ADP or adrenaline, before (pre) and 4-6 months after (post) taking the
contraceptivepill in agroup ofsmokers and non-smokers. * p<0-05 compared
with baseline. Values are mean ± standard deviation.
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used in this study are widely used as an index of platelet function. Our results
confirm thoseof other investigatorsthat thecombined contraceptive pill increases
platelet aggregation as assessed by ADP. The reasons why we were unable to
show an effect with adrenaline are unclear since platelet aggregation has been
shown to be increased by other investigators using similar techniques.4 The fact
that adrenaline failed to induce platelet aggregation in some ofthe subjects, thus
reducing the study number, could be a factor.
Although it is generally assumed that the techniques used in this study give some
indication of platelet aggregation in vivo, the methods used are artificial and use
supraphysiological doses of aggregating agents. The finding of increased platelet
aggregation does not necessarily imply that this is associated with an increased
risk of thrombosis. This study suggests that smoking in patients receiving the
contraceptive pill has little effect on platelet function which is in keeping with
most of the previous published literature. The principal effects of smoking would
appear to be on the vascular endothelium 10, 1 12 and those of the combined
contraceptive pill to be on the platelet.
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